• Increase Font

    Direct-acting antivirals prevent liver cancer recurrence

    Direct-acting antiviral (DAA) therapy in patients infected with hepatitis C virus (HCV) with hepatocellular carcinoma (HCC) can prevent recurrences for those on the transplant waiting list who have an initial response to locoregional therapy, according to a new study.

    DAAs have been widely touted to cure HCV, but some controversy was raised recently when small, uncontrolled studies with only historical controls found an increased risk of HCC recurrence after treatment of chronic HCV.

    “DAAs offer so much benefit in curing HCV. Our study confirms that DAAs are beneficial and should be used in patients on the transplant waiting list with HCC who have achieved initial response to locoregional therapy,” Annsa Huang, MD, resident in internal medicine at the University of California at San Francisco, told Medical Economics.

    Huang presented data at a late breaking abstract () at the 2017 International Liver Congress.


    Next: Study details


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow